Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Value of 18F-FES-PET/CT in Predicting the Efficacy of Fulvestrant as First-line Treatment in Postmenopausal Patients With Hormone Receptor-positive Advanced Breast Cancer - a Multicenter Prospective Study

NCT03768479 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT03768479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03768479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Value of 18F-FES-PET/CT in Predicting the Efficacy of Fulvestrant as First-line Treatment in Postmenopausal Patients With Hormone Receptor-positive Advanced Breast Cancer - a Multicenter Prospective Study
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Not applicable
Overall status
Unknown status
Start date
March 5, 2017
Completion date
March 31, 2019
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-positive breast cancer, fulvestrant